Fri, Mar. 20, 2:18 PM| Comment!
Dec. 30, 2014, 1:49 PM
- In keeping with the trend of biotech focused launches in the last quarter, the ALPS Medical Breakthroughs ETF (Pending:SBIO) will be the last launch of 2014.
- SBIO is designed to capture research and development opportunities in the biotechnology and pharmaceutical industries through small-cap and mid-cap biotechnology stocks listed in the U.S.
- Firms with with one or more drugs in Phase II or Phase III FDA clinical trials, with a market cap between $200 million and $5 billion, will be prime candidates for investment.
- Other domestic biotech ETFs: XBI, BBH, FBT, PBE, BBC, BBP
Dec. 19, 2014, 1:55 PM| Comment!
Dec. 17, 2014, 10:51 AM
- The BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) will track an index of biotechnology companies with a principal focus on running human clinical trials, while the BioShares Biotechnology Products Fund (NASDAQ:BBP) will cover biotechnology companies with one or more drugs approved by the FDA and in commercial production.
- Both ETFs feature an equal weight index strategy, giving smaller firms a chance to make a meaningful impact on fund movements.
- “Our BioShares funds are designed with the current biotechnology market in mind and offer investors unique and diversified portfolios of entrepreneurial biotechnology stocks by applying our rules-based index methodology,” said LifeSci Index Partners co-founder, Paul Yook in a statement.
- Other biotech ETFs: XBI, BBH, FBT, PBE
Oct. 31, 2014, 12:47 PM
- The ARK Genomic Revolution Multi-Sector ETF (NYSEARCA:ARKG) is an actively managed fund that focuses on companies linked to the genomic industry across a number of sectors.
- The ARK Innovation ETF (NYSEARCA:ARKK) will cover all three investment themes ARK now offers ETF coverage of; industrials through the ARK Industrial Innovation ETF (NYSEARCA:ARKQ), technology through the ARK Web x.0 ETF (NYSEARCA:ARKW) and genomics with ARKG.
- "Our composite fund is a product of our approach to active management and can bring balance back to portfolios that have become increasingly benchmark-sensitive. Pulling across industries including life sciences, robotics, energy storage, social media, and cloud computing, ARKK will hold some of the most dynamic and innovative companies in the world," stated Cathie Wood, founder and CEO of ARK Investment Management, in a press release.
- Other broad technology ETFs: IPK, IXN
- Other biotech ETFs: XBI, BBH, FBT, PBE
Oct. 26, 2014, 9:44 AM
- Both groups experienced large corrections from February through April and have since corrected, but Biotech has massively outperformed the internet group over the last couple of months.
- Since 2013, Technology SPDR (NYSEARCA:XLK) +38.4%, iShares NASDAQ Biotechnology Index (NASDAQ:IBB) +109.3%.
- Source: Bespoke
- ETFs: XLK, XBI, VGT, BBH, SOXL, FBT, FDN, PBE, TECL, USD, SMH, IYZ, TDIV, IYW, ROM, VOX, SOXX, XSD, SOXS, PBS, TECS, FTEC, RYT, IGV, IGM, QTEC, FXL, PSI, PSCT, IGN, SSG, MTK, REW, PXQ, XTL, XSW, PSJ, PTF, FCOM, LTL, TLL
Jul. 8, 2014, 12:26 PM
- Leading this week's decline are a lot of the same names which led March's "momo" selloff, among them the biotechs (XBI -4.5%) and social media (SOCL -4.4%). Also familiar, small caps (IWM -1.5%) are off more than the other major indexes.
- Doing their jobs are the low volatility ETFs like SPLV (SPLV) and USMV (USMV -0.2%), as well as defensive sectors like the utilities (XLU +0.6%).
- Raymond James' typically bullish Jeffrey Saut is out with a note calling for the first decent pullback of the year - a 10-12% decline - to commence later this month or early August, and he suggests investors begin raising cash.
- Biotech ETFs: XBI, BBH, FBT, PBE
- Low-vol ETFs: SPLV, LGLV, CFA, CFO
- Utility ETFs: XLU, IDU, VPU, UPW, FUTY, RYU, FXU, PUI, SDP, PSCU
Jun. 9, 2014, 2:53 PM
- Those ETFs with more small- and mid-cap exposure like the SPDR S&P Biotech ETF (XBI +5.7%) and the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE +7.4%) are partying. It also turns out the XBI and PBE are the two largest holders of Idenix stock.
- Biotech ETFs with a focus on large caps - the iShares Nasdaq Biotechnology ETF (IBB +0.5%) and the Market Vectors Biotech ETF (BBH +0.4%) - are having more subdued sessions.
- Previously: Merck buys Idenix
- The rally in small cap biotech fueling a positive session for small caps overall, with the Russell 2000's (IWM +0.7%) gain outpacing the flat action in the big-cap averages.
May. 13, 2014, 11:37 AM
- General Electric (GE -0.1%) introduces SPINlab, a Carbon-13-based hyperpolarizing system that enables researchers to visualize metabolic activity at the cellular level using magnetic resonance imaging (MRI). The system simplifies MRI-based metabolic research by providing reliable access to hyperpolarized compounds in a dedicated unit.
- The system enables the non-invasive real-time study of biochemical changes in disease processes by improving the sensitivity of MRI more than 20,000-fold.
- Related tickers: IBB, XBI, BIB, BBH, FBT, PBE, BIS
May. 12, 2014, 12:10 PM
- The South Korean colossus is investing $2B in the biotech arena in an effort to drive growth from its $347B revenue base. Its main initial focus will be biosimilars with a planned 2016 launch in Europe of an Enbrel biosimilar and a 2017 launch of a Remicade biosimilar.
- The global market for biosimilars, while lagging in the U.S. due to regulatory uncertainty, is expected to grow to $24B by 2019.
- According to unit chief Christopher Hansung Ko, "Our mandate is to become No. 1 in everything we enter into, so our long-term goal is to become a leading pharmaceutical company in the world."
- Related tickers: (IBB) (JNJ) (AMGN) (BIIB) (XBI) (SSNLF) (SSNGY)
May. 9, 2014, 9:59 AM
- The downtrend in the biotech sector that began on February 26 ain't done yet. On a technical basis, (IBB +0.1%) has been trying to hold on to its wobbly base since its snap back move on April 15. Volume has dried up as the index struggles to stay above the key support level of the 200-day MA. This is not encouraging action for longs.
- The relative strength line has dropped from a best-possible rating of 99 down to 68 with no upturn in sight.
- Biotech investors should keep their powder dry until the money flow turns decidedly positive. Based on the chart, there is no indication that this is happening yet.
- ETFs: XBI, BIB, BBH, FBT, PBE, BIS
May. 8, 2014, 7:35 AM
- China intends to end price limits on low-cost drugs after the controls caused quality problems and shortages.
- China's economic planning body, the National Development & Reform Commission, will lift price caps on 280 drugs provided by Western companies and 250 Chinese patent medicines.
- Sanofi (SNY) and Pfizer (PFE) said it's too early to ascertain the impact of the new policy. Other companies that could be affected include GlaxoSmithKline (GSK).
- ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, BIS, FHLC, PSCH, RYH, PTH, DRGS, RXD
Apr. 25, 2014, 2:49 PM
- Much of the high tech equipment hospitals use can be easily hacked and could pose a significant danger to patients according to the head of information security at Essentia Health.
- Imaging equipment, insulin pumps, defibrillators and refrigerators that store blood and drugs are examples of networked gear that have remote access control features.
- The devices' software is plagued by common security holes like weak passwords, lack of authentication to access, easy-to-determine default and hard-coded passwords and embedded web servers and administrative interfaces that make it easy to identify and manipulate devices once found on the network.
- Hospital are apparently just waking up to the potential risks.
- Last spring, the FDA and DHS issued a notice to the health care industry about problems with hard-coded passwords after researchers found issues in ~300 devices.
- ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, IHI, BIS, IHF, FHLC, XHS, PSCH, RYH, XHE, PTH, DRGS, RXD
Apr. 25, 2014, 1:31 PM
- Today's selloff is following the pattern of most in the past few weeks, with the small caps (IWM -1.9%) and tech (QQQ -1.5%) leading the way. Pacing declines in the Nasdaq are a 8.8% dive in Amazon post-earnings and a 4.6% fall in Facebook. Setting tongues wagging in FB - but hardly a huge deal - is the sale of another 283K shares by Sheryl Sandberg, bringing her holdings down to 8.7M shares.
- The liquidation in biotech has previously been a convenient excuse for small cap selloffs, but the IBB is off just 1.4% today, outperforming the Russell 2000.
- What's working? Utilities again. The XLU +0.8% today and +13% this year, outperforming the Russell 2000 by about 1.6K basis points.
- Small cap ETFs: IWM, TZA, TNA, UWM, VB, IJR, SLY, RWJ, URTY, SCHA, TWM, RWM, SRTY, SAA, DWAS, VTWO, SDD, VIOO, JKJ, RSCO, SBB, FYX, XSLV, EWRS, TWOK, SMLV, PXSC
- Utility ETFs: XLU, IDU, VPU, NLR, GRID, JXI, NUCL, DBU, IPU, UPW, RYU, PUI, FUTY, FXU, SDP, PSCU, UTLT
- Biotech ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
Apr. 25, 2014, 12:46 PM
- In what may be the first step in discovering how to eradicate African sleeping sickness, scientists decipher the dreaded tsetse fly's genome. The decade-long effort involved more than 149 scientists from 78 research institutions in 18 countries. It's genome contains ~12K genes and 366M letters of genetic code.
- The fly carries the parasitic microorganism, Trypanosoma brucei, that causes Trypanosomiasis in 36 sub-Saharan countries. It transmits the pathogen in its saliva when it bites a victim. The disease is fatal if untreated.
- The disease also afflicts cattle with a disease called Nagana.
- The bug's biology is unusual. It gives birth to live young, it nourishes larvae inside the uterus with a milk-like substance, it finds the colors blue and black irresistible and it feeds exclusively on blood.
- Researchers hope to identify a tsetse-specific reproductive inhibitor that has no mammalian toxicity.
- The tsetse fly has been in mammals' ointment for at least 34M years.
- Sleeping sickness afflicts far fewer people than malaria and dengue.
- In 2012 there were 7,216 recorded cases according to WHO, but the incidence is most certainly under-reported.
- ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
- ETFs: IRY, IXJ
Apr. 22, 2014, 12:14 PM
- The Health Care M&A Report tallies Q1 2014 deal volume of 239 transactions valued at $49.6B. The number of deals for Q4 2013 and Q1 2013 were 278 and 212, respectively. The $49.6B total value was up 11% versus Q4 and up 217% versus Q1.
- The most deals were consummated in long-term care (60), pharmaceuticals (33), biotech (26) and devices (25).
- Healthcare ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, IHI, BIS, IHF, FHLC, XHS, PSCH, RYH, XHE, PTH, DRGS, RXD
XBI vs. ETF Alternatives
The SPDR® S&P® Biotech ETF, before expenses, seeks to closely match the returns and characteristics of the S&P Biotechnology Select IndustryTM Index. Our approach is designed to provide portfolios with low portfolio turnover, accurate tracking, and lower costs.
See more details on sponsor's website
See more details on sponsor's website
Other News & PR